Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Mylan Inc patents


Recent patent applications related to Mylan Inc. Mylan Inc is listed as an Agent/Assignee. Note: Mylan Inc may have other listings under different names/spellings. We're not affiliated with Mylan Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Mylan Inc-related inventors


Process for the enantiomeric resolution of apremilast intermediates

A process for the resolution of racemic 2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine using novel chiral salts is disclosed. An l-phenylalanine p-toluene-sulfonamide salt of (s)-2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine and a di-p-toluoyl-l-tartaric acid salt of (s)-2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine are also provided.. ... Mylan Inc

Process for the preparation of amorphous idelalisib and its premix

Processes for the preparation of amorphous idelalisib are provided. Processes for the preparation of a premix of amorphous idelalisib are also provided.. ... Mylan Inc

Polymorphic forms of afatinib dimaleate

The present disclosure relates to amorphous and crystalline forms of 2-butenamide, n-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3s)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-,(2e)-, (2z)-2-butenedioate (1:2) (afatinib dimaleate). The present disclosure also relates to process for the preparation of amorphous and crystalline forms of afatinib dimaleate. ... Mylan Inc

Lithographic printing plates precursors comprising a radiation sensitive imageable layer with a crosslinked surface

There are free radical scavengers of formula (pm-l)n-tq. Also provided are negative-working lithographic printing plate precursors comprising a hydrophilic substrate and a nir photopolymerizable or uv-violet photopolymerizable imageable layer coated on the hydrophilic layer, the imageable layer also being photopolymerizable by visible light, the imageable layer having an outer surface and a thickness, the outer surface of the imageable layer being uniformly, and partially or completely crosslinked down to a depth corresponding to at most about 70% of the thickness of the imageable layer.. ... Mylan Inc

Medication packaging and dose regimen system

A medicament dispensing container includes a first wall connected with a second wall and defines a cavity therebetween. The walls are movable between an open configuration and a closed configuration. ... Mylan Inc

Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

An amorphous form of tenofovir alafenamide hemifumarate and process for the preparation of the same. A premix of amorphous tenofovir alafenamide hemifumarate with pharmaceutically acceptable excipients and process for the preparation of the same are also disclosed.. ... Mylan Inc

Amorphous empagliflozin

The present disclosure relates to solid dispersion of amorphous empagliflozin and its process thereof.. . ... Mylan Inc

Double disk transdermal system

A double disk dermal device for administration of one or more active agents to the skin or mucosa of a host, in particular a patch is described including: a) active reservoir film layer; b) a backing overlay adjacent to the active reservoir film layer extending beyond the perimeter of the reservoir layer in all directions; c) second overlay backing layer with a coating of pressure sensitive adhesive which is adjacent to the first backing overlay extending beyond the perimeter of the first backing overlay in all directions; and d) a removable release liner. A method of making the device is also provided.. ... Mylan Inc

Double disk transdermal process

A double disk dermal device for administration of one or more active agents to the skin or mucosa of a host, in particular a patch is described including: a) active reservoir film layer; b) a backing overlay adjacent to the active reservoir film layer extending beyond the perimeter of the reservoir layer in all directions; c) second overlay backing layer with a coating of pressure sensitive adhesive which is adjacent to the first backing overlay extending beyond the perimeter of the first backing overlay in all directions; and d) a removable release liner. A method of making the device is also provided.. ... Mylan Inc

Method for making a multilayer adhesive laminate

A method allows for rapid manufacture of relatively thick adhesive coatings using a continuous process, where a single thin coating is continuously converted into a single thicker adhesive laminate. An exemplary process includes the steps of: (1) producing a web having a first surface with an adhesive layer and a second surface with a release liner; (2) slitting the web longitudinally into a first section and a second section; (3) laminating a backing film to the adhesive layer of the first section; (4) removing the release liner of the laminate of step (3) exposing the adhesive layer of the first section; and (5) laminating the second section to the laminate of step (4), wherein the adhesive layer of the laminate of step (4) is combined with the adhesive layer of the second section.. ... Mylan Inc

Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists

Compositions and methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders are provided. The compositions provided herein are nebulizable compositions comprising quaternary ammonium muscarinic receptor antagonists. ... Mylan Inc

Medication delivery system and method

A medication delivery system includes a medical server configured to send and receive and process data, a medication device configured to administer a preselected medication, a sensor circuit configured to detect selected parameters relating to medication delivery and transmit information, a transmission hub configured to communicate with the medical server and the sensor circuit. The transmission hub is configured to receive a signal from the sensor circuit and exchange the information. ... Mylan Inc

Processes for the preparation of intermediates of raltegravir

The present disclosure provides a process for the preparation of 2-(2-amino propan-2-yl)-n-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxamide by debenzylation of benzyl(2-{4-[(4-fluorobenzyl)carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl}propan-2-yl)carbamate. This process may be used in the synthesis of raltegravir and pharmaceutically acceptable salts thereof.. ... Mylan Inc

Process for the preparation of canagliflozin

A process for the preparation of canagliflozin. The process may be effectively implemented on an industrial scale. ... Mylan Inc

08/31/17 / #20170246082

Container for storage of a medicament

Various embodiments are described for a container for storage of a medicament, the container comprising a surface having at least a cavity configured to store at least one dose of the medicament; and a covering disposed over at least the cavity of the surface and comprising at least two adjacent edges and a set of perforations disposed on the covering and spaced apart from the at least two adjacent edges of the covering. A container comprising a sheet of separable units and methods for use are described.. ... Mylan Inc

08/24/17 / #20170239144

Medication packaging and dose regimen system

A medicament dispensing container comprises a first wall and a second wall defining a cavity therebetween. At least one member is connected to at least one of the walls and is disposable in the cavity. ... Mylan Inc

08/17/17 / #20170231867

Medication packaging and dose regimen system

A medication container includes a body comprising a neck portion and defining a cavity that includes at least one compartment. At least one closure member disposed with the neck portion in alignment with at least one of the at least one compartment, the at least one closure member being rotatable relative to the body. ... Mylan Inc

07/06/17 / #20170190168

Lithographic printing plates precursors comprising a radiation sensitive imageable layer with a crosslinked surface

There are free radical scavengers of formula (pm-l)n-tq. Also provided are negative-working lithographic printing plate precursors comprising a hydrophilic substrate and a nir photopolymerizable or uv-violet photopolymerizable imageable layer coated on the hydrophilic layer, the imageable layer also being photopolymerizable by visible light, the imageable layer having an outer surface and a thickness, the outer surface of the imageable layer being uniformly, and partially or completely crosslinked down to a depth corresponding to at most about 70% of the thickness of the imageable layer.. ... Mylan Inc

06/22/17 / #20170174719

Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent

The present disclosure relates to an improved process for the purification of fluticasone propionate by: a) dissolving fluticasone propionate in a ketone solvent to produce a mixture, b) heating the mixture slowly for 1-2 hours to get a clear solution, c) adding water to the step (b) solution at 50-60° c., d) cooling to −5° c. To 10° c., and e) isolating fluticasone propionate.. ... Mylan Inc

05/11/17 / #20170129893

Novel crystalline form of levomefolate

The present disclosure relates to crystalline forms of levomefolate calcium). The present disclosure also relates to a process for the preparation of crystalline forms of levomefolate calcium.. ... Mylan Inc

04/06/17 / #20170096395

Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base

The present disclosure provides novel crystalline forms of cabozantinib (s)-malate, designated as form-m1, m2, m3 and m4 and novel crystalline forms of cabozantinib free base, form-m1, m2 and m3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (s)-malate form n-1.. ... Mylan Inc

03/30/17 / #a transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix.

Mylan Technologies, Inc.

. . ... Mylan Inc

03/23/17 / #20170079734

Medicament storage, dispensing, and administration system and method

Various exemplary embodiments relate to an electronic device for dispensing a medicament. The electronic device may include a medicament storage case or an electronic medicament device. ... Mylan Inc

02/23/17 / #20170049724

Extended-release dosage form

Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrounding the intermediate coating comprising a ph independent polymer. Also provided is a pharmaceutical formulation comprising two bead populations wherein each of the first and second bead populations have a different drug release profile. ... Mylan Inc

02/09/17 / #20170035911

Amorphous cobicistat solid dispersion

The present disclosure relates to a solid dispersion of amorphous cobicistat and methods of its preparation. Cobicistat may be complexed with a pharmaceutically acceptable carrier such as β-cyclodextrin or hydroxy! propyl β-cyclodextrin. ... Mylan Inc

02/02/17 / #20170028063

Stable protein formulations comprising a molar excess of sorbitol

A stable pharmaceutical formulation comprising a protein of interest, sorbitol and polyethylene glycol (peg). The sorbitol and protein is present in a molar ratio of 550 to 700 mole of sorbitol: 1 mole of protein and the peg to protein is present in the molar ratio of 2-50:1. ... Mylan Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Mylan Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mylan Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###